Scott alfred fretzin, m

Scott Alfred Fretzin, MD
Dawes Fretzin Clinical Research Group, LLC Education
Indiana University School of Medicine (Indianapolis, IN)Dermatology Residency, 1997 University of Chicago Pritzker School of Medicine (Chicago, IL)Internal Medicine Internship, 1994 University of Chicago Pritzker School of Medicine (Chicago, IL)Medical Doctorate, 1993 Washington University (St. Louis, MO)Bachelor of Arts in Philosophy, 1989 Professional Experience
Dawes Fretzin Clinical Research Group, LLC (Indianapolis, IN)
Investigator, 2004-Present
Dawes Fretzin Dermatology Group, LLC (Indianapolis, IN)
Dermatologist, 1999-Present
BellFlower County Clinic (Indianapolis, IN)
Dermatologist (part-time), 1997-Present
Indiana University School of Medicine (Indianapolis, IN)
Volunteer Assistant Professor Clinical Dermatology, May 2011- Present
Indiana University School of Medicine (Indianapolis, IN)
Clinical Assistant Professor, 1997- May 2011
Dawes Dermatology Group (Indianapolis, IN)
Dermatologist, 1997-99
Honors and Awards
Honorable Mention, Young Investigators Competition, Dermatol Surg Genetics Society of America Summer Research Fellowship 1987-88 Scholarship and Leadership Award, Kappa Sigma National Fraternity Scott Alfred Fretzin, MD
Clinical Study Experience (Other than Dawes Fretzin Clinical Research Group, LLC)
Genital Warts
Sponsor: 3M
Safety and efficacy trial evaluation 5% Imiquimod Cream application to external genital
warts and an extended treatment area; 1999-02 Diabetes
Sponsor: Takeda
Acting Agent: Quintiles, Inc.
An open-label, long-term extension study of voglibose (AO_128) in Type II Diabetes
Mellitus patients; March 1997 to June 1999 Atopic Dermatitis
Sponsor: Connetics Therapeutics
An open-label, follow-on study of the safety and efficacy of Recombinant Interferon-y 1b
in subjects with moderate to severe atopic Dermatitis; September 1996 to December1998 Atopic Dermatitis
Sponsor: Connetics Therapeutics
A Phase III study of the safety and efficacy of Recombinant Interferon-y 1b in subjects
with moderate to severe atopic Dermatitis; September 1996 to April 1998 Diabetes
Sponsor: Takeda
Acting Agent: Covance, Inc
A double-Blind, Placebo-Controlled, Randomized, Dose-Titration Study to Evaluate the
Safety and Efficacy of Pioglitazone; January 1997 to December 1998 Scalp Psoriasis
Sponsor: Connetics Therapeutics
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Betamethasone
Valerate Foam in Treating Scalp Psoriasis; April 1997 to December 1997 Bronchitis
Sponsor: Bristol-Myers Squibb
A Double-blind Multicenter Compartive Study of Cefprozil (250mg bid) versus
Cefuroxime Axetil (250mg bid) in the Treatment of Bronchitis; December 1995 toApril 1997 Non-Insulin Dependent Diabetes Mellitus
Sponsor: Parke Davis
A 20-week, Double-Blind, Randomized Study of Troglitazone (CL-991) in patients with
Non-Insulin Dependent Diabetes Mellitus; June 1995 to May 1997 Diabetes
Sponsor: Takeda
Acting Agent: Quintiles, Inc
A Randomized, Double-Blind, Placebo-Controlled, Six-Month, Safety and Efficacy Trial
of 0.1, 0.5, 1, 2, 5 mg TID of Voglibose (AO-128) in Type II Diabetes MellitusPatients; October 1996 to December 1997 Scott Alfred Fretzin, MD
Clinical Study Experience (Cont)
Osteoarthritis
Sponsor: Merck
A Double-Blind, Randomized, Multicenter Study to Compare the Safety of Dexibuprofen
Lysine with Ibuprofen for Long-Term Treatment of Osteoarthritis; September 1996 to Rheumatoid Arthritis
Sponsor: Boston Life Sciences, Inc
A Double-Blind, Randomized Study of Therafectin 6 grams/day compared to Placebo in
Patients with Rheumatoid Arthritis Withdrawn from their Nonsteroidal Anti-Inflammatory Drug Therapy; June 1996 to July 1997 Psoriasis
Sponsor: Sergen, Inc
Phase II Randomized, Double-Blind, Placebo-Controlled Trial of DAB389IL-2 in Patients
with Moderate to Severe Plaque-Type Psoriasis; June 1995 to October 1996 Xerostomia and Keratoconjunctivitis Sicca
Sponsor: Snowbrand Milk Products, Acting Agent: Pharmaco LSR
A pilot study of SNI-2011 in patients with Sjogren's Syndrome experiencing xerostomia
and keratoconjunctivitis Sicca; July 1995 to December 1996 Intermittent Claudication
Sponsor: Marion Merrell Dow
Dose-Response Evaluation of Beraprost Sodium IR Tablets in Treatment of Intermittent
Claudication; October 1995 to December 1996 Articles and Publications
Krueger JG, Fretzin S, Suárez-Fariñas M, Haslett PA, Phipps KM, Cameron GS, McColm J, Katcherian A, Cueto I, White T, Banerjee S, Hoffman RW. “IL-17A is
essential for cell activation and inflammatory gene circuits in subjects with
psoriasis.” J Allergy Clin Immunol. 2012 Jul;130(1):145-154.e9. Epub 2012 Jun 5.
Gottlieb, A., Menter, A., Mendelsohn, A., Yaung-Kaung, S., Guzzo, C., Fretzin, S., Kunynetz, R., Kavanaugh, A. “Ustekinumab, a human interleukin 12/23
monoclonal antibody, for psoriatic arthritis: randomised, double-blind,
placebo-controlled, crossover trial.” Lancet, 2009 Feb 21; 373:633.
Papp, K., Bressinck, R., Fretzin, S., Goffe, B., Kempers, S., Gordon, K., Caro, I., Walicke, P., Wang, X., Mentor, A. “Safety of efalizumab in adults with chronic
Moderate to severe plaque psoriasis: A phase IIIb, randomized, controlled
trial.” International Journal of Dermatology, May 2006; Vol 45, Number 5: 605-614.
Crowley, J., Fretzin, S., Sobell, J. “New Treatment Options for Psoriasis Involving
the Hands and Feet.” Biologic Bulletin, March 2006.
Fretzin, S. “Recent Advances in the Treatment of Psoriasis with Efalizumab
Therapy.” US Dermatology Review, 2006 Issue II: 12-14.
Fretzin, S. “Managing Cases of Chronic, Moderate-to-Severe Plaque Psoriasis
Involving the Hands and Feet with Raptiva®” DermPA Today, Spring 2006; Vol 3,
Number 1:4-5.
Fretzin, S. “Managing Cases of Chronic, Moderate-to-Severe Plaque Psoriasis
Involving the Hands and Feet with Raptiva®” DermNurse, Spring 2006; Vol 2,
Number 1:3-4.
Scott Alfred Fretzin, MD
Articles and Publications (Cont)
Fretzin, S. “Managing Cases of Chronic, Moderate-to-Severe Plaque Psoriasis
Involving the Hands and Feet with Raptiva®” Derm Resident, Spring 2006; Vol 5,
Number 5:5-6.
Fretzin S., Crowley, J., Jones, L., Young, M., Sobell, J. “Successful Treatment of
Hand And Foot Psoriasis with Efalizumab Therapy.” Journal of Drugs in
Dermatology. October 2006; Vol 5, Issue 9; 838-846.
Fretzin S., Dawes K. J Am Acad Dermatol 2005; 52:P182. Abstract P2745.
S. Fretzin. “Answer All Your Patients’ Questions About STDs.” Skin Aging 2000; 8
R. Huff, S. Fretzin, C. Lewis. “Penile Eruption on a Diabetic Man.” Arch Dermatol
R Huff, S. Fretzin. “Vesicular Eruption on the Chest and Back.” Archives of
S. Fretzin. “Ringworm and Molluscum Contagiosum.” Indiana Amateur Wrestling
M. Fretzin, S. Fretzin, D. Fretzin. “A Papulonecrotic Eruption in a Young Man.” Arch
T. Eads, S. Fretzin, C. Lewis. “Pruritic, Painful Eruption.” Arch Dermatol 1998;
S. Fretzin. “Introduction to the Terminology of Ethics.” Ethics Workbook for
Dermatology Residency Directors. 1998.
S. Fretzin, W. Beeson, W. Hanke. “Ignition Potential of the 585 nm Pulsed Dye
Laser: Review of the Literature and Safety Recommendations.” Dermatol Surg
1996; 22 699-702.
G. Westhoven, S. Fretzin, C. Lewis. “A Woman with Lung Cancer and Exfoliative
Dermatitis.” Arch Dermatol 1997; 133: 499-504.
D. Fretzin, J. Sloan, K. Beer, S. Fretzin. “Eccrine Syringofibroadenoma: A Clear Cell
Variant.” Am.J. of Dermatopathology 1995;17 (6): 591-593
S. Fretzin, B. Allen, A. Vane Daal, S. Elgin. “A Drosophila melanogaster H3.3 cDNA
Encodes a Histone Variant Identical with the Vertebrate H3.3.” Gene. 107
(1991) 341-342.
F. Booyse, R. Bruce, M. Grover, S. Fretzin, J. Karkov, H. Modi, L. Casey. “Rapid
Release of Plasminogen Activators From Cultured Human Umbilical Vein
Endothelial Cells.” Blood. 66#5 (1985).
Presentations/Posters
World Congress of Dermatology. C. Leonardi, J. Sobell, S. Fretzin, H. Sofen, T.
Hamilton, Y. Chen, C, Ivor, A. Menter. Phase IV Study to Evaluate the Safety andEfficacy of Efalizumab in the Treatment of Hand and Foot Plaque Psoriasis. October,2007 68th SID Annual Meeting. A. Ehrlich, S. Fretzin, W. Werther, Y. Chen, I. Caro, D.
Pariser. Prevalence of Cardiovascular Risk Factors by Psoriasis Severity in Biologic-Treated Patients: The RESPONSE Cohorts. May 9-12, 2007.
Australasian College of Dermatologists 39th Annual Scientific Meeting. S. Fretzin,K. Dawes, AC Rundle, I Caro. Safety of a topically applied novel small moleculeinhibitor of the Hedgehog signaling pathway in subjects with basal cell carcinoma. May14-17, 2006.
Scott Alfred Fretzin, MD
Presentations/Posters (Cont)
The American Academy of Dermatology Meeting (64th Annual). J. Sobell, S. Fretzin.
Case studies of efalizumab in hand and foot psoriasis. March 3-7, 2006.
The American Academy of Dermatology Meeting. S. Fretzin, A. Menter, R. Langley,D. Cohen. Therapeutic Strategies and Treatments for Psoriasis (CME/CD-ROM).
February, 2005.
The American Academy of Dermatology Meeting. S. Fretzin, K. Dawes. Efficacy andSafety of Efalizumab for Patients with Palmoplantar Pustulosis. February, 2005.
The American Academy of Dermatology Meeting. S. Fretzin, J. Cotton, A. Hood.
Aleukemic Lymphoblastic Leukemia Cutis in a 14 month-old girl. San Francisco,California. 1997.
The American Society for Dermatopathology Meeting. J. Cotton, S. Fretzin, A. Hood.
Cutaneous Lymphoblastic Lymphoma in children. Two case reports and review of theliterature. San Francisco, California. March, 1997.
The United States and Canadian Academy of Pathology Meeting. J. Cotton, S. Fretzin,R. Neiman. Cutaneous Lymphoblastic Lymphoma in children. Two case reports andreview of the literature. Orlando, Florida. March 1997.
St. Vincent’s Hospital Dermatopathology Conference. S. Fretzin. Degos’ Syndrome.
January 1997.
St. Vincent’s Hospital Dermatopathology Conference. S. Fretzin. Well’s Syndrome.
September 1996.
The American Academy of Dermatopathology Meeting, 1996. S. Fretzin, H. Faust.
Atypical Cutaneous reaction to Benazepril with histologic features of Mycosis Fungoides.
The American Society for Cell Biology Regional Meeting. Poster Presentation. S. Elgin,A. Van daal, S. Fretzin, E. White, M. Gorovsky. “Histone Variants H2Avd and H3.3 ofDrosophila melangaster.” March, 1990.
UCLA Symposium on Transcriptional Control of Cell Growth. A. Van daal, S. Fretzin, E.
White, M. Gorovsky, S. Elgin. “Histone Variants H1Avd and H3.3. of Drosophilamelanogaster.” January, 1990.
Other Research Experience
Washington University of St. Louis, Dept. of Biology, Sarah C. Elgin, Ph.D.;Characterization of Drosophila melanogaster Histone Variant Gene.
Barnes Hospital, Dept. of Dermatology, Eugene Bauer, M.D.; Collagenase assays for research in Epidermolxsis Bullosa.
Michael Reese Hospital, Dept. of Immunology, Enrique Beckman M.D.; GeneRearrangement of Lymphomas.
Michael Reese Hospital, Dept. of Immunology, Francoise Booyse, Ph.D.; Release of Plasminogen activators from human endothelial cells.
Scott Alfred Fretzin, MD
License/Certifications
Board Certified in Dermatology, 1997Indiana State License #01044060ACLS CertifiedCITI Certification, February 2012 Professional Societies
American Academy of DermatologyIndiana Dermatologic SocietyAmerican Medical Association

Source: http://dawesfretzinresearch.net/wp-content/uploads/2013/05/FretzinCV.pdf